A Phase 2 clinical trial, GEOMETRY mono-1, evaluating Novartis' (NVS -0.4%) capmatinib (INC280) in adult patients with advanced non-small cell lung cancer (NSCLC) with MET exon-14 skipping mutations showed a treatment benefit. The results were presented at ESMO in Munich.
The overall response rate (ORR) was 72.0% (n=18/25) in treatment-naive patients and 39.1% (n=27/69) in previously treated patients.
No new safety signals were observed. 83.8% of treated patients experienced an adverse event (AE), including 33.1% with grade 3 (serious) or grade 4 (life-threatening) AEs.
MET mutation-positive NSCLC represents about 3-4% of total cases.
Novartis in-licensed capmatinib, an oral MET inhibitor, from Incyte (INCY -1.9%) in 2009.